 |
|
|
|
 |
|
|
| Article 1 to 7 out of 7 concerning Silence Therapeutics plc
|
-
Silence Therapeutics to receive $1.9m Milestone Payment as Pfizer and Quark commence Phase II Trial
(01 Aug 2008)
Silence Therapeutics plc announced that its partner, Quark Pharmaceuticals Inc together with Pfizer, has commenced a Phase II clinical trial with RTP-801i-14 (PF-4523655), a small interfering RNA (siRNA) therapeutic product based on Silence's ...
-
Silence Therapeutics' Group CEO resigns
(21 Jul 2008)
Silence Therapeutics plc announced that for personal reasons, Jeffery Vick, has resigned as Group CEO and left the Company. The Board of Directors has appointed Iain Ross, currently Non-Executive Chairman, full time Chairman and Group CEO with ...
-
Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
(18 Mar 2008)
Silence Therapeutics plc announced a collaboration with AstraZeneca, focused on the development of a range of novel approaches for the delivery of siRNA molecules. The deal builds on Silence Therapeutics' leading expertise in the delivery of siRNA ...
-
Silence Therapeutics announces that the entire shareholding held by Introgen has been placed with existing and new shareholder
(21 Jan 2008)
Silence Therapeutics plc announced that a number of existing institutional shareholders have increased their shareholdings in the Company, while several additional investors have become new shareholders. These shareholders have purchased their ...
-
Silence Therapeutics RNAi Lead Compound Atu027 Successfully Completes 28-Day Toxicology Studies
(12 Sep 2007)
Silence Therapeutics plc announced that its lead compound, Atu027, has successfully completed pre-clinical, 28-day toxicology studies. Silence Therapeutics has identified a dose range for Atu027, a systemically delivered RNAi compound, at which ...
-
Silence Therapeutics And Quark Pharmaceuticals Expand Strategic Licensing Agreement.
(03 Aug 2007)
Silence Therapeutics plc and Quark Pharmaceuticals, Inc., announced an expansion of their current strategic technology licensing agreement.In April 2005 the companies signed an Option and Licence Agreement, which provided Quark with access to ...
-
Silence Therapeutics strengthens Management Team with the appointment of CEO
(31 Jul 2007)
Silence Therapeutics plc announced that it has appointed Jeffery Scott Vick as Group CEO in order to strengthen its core management team as the Company seeks to expand its business partnerships. Jeff Vick (45) is a B.S. chemistry graduate of the ...
|
|
|
|
|
Top
